The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024
US pharma major Eli Lilly and Egyptian firm EVA Pharma have entered into an agreement to expand access to Olumiant (baricitinib) to an estimated 20,000 people in 49 low- to middle-income countries in Africa by 2030. 6 September 2024
Novartis is building two new radioligand therapy (RLT) manufacturing facilities in the USA to enhance its supply chain for cancer treatments. This move supports the growing use of RLTs, a form of precision medicine that targets tumors with radiation. 6 September 2024
Belgium’s largest drugmaker UCB announced a strategic divestment deal in China, underscoring its strategic shift towards innovation and partnership in one of the world’s fastest-growing pharmaceutical markets. 27 August 2024
The UK’s largest pharma company AstraZeneca has rejected claims that it is moving its vaccine operations to the USA, according to media reports. 23 August 2024
Mitsubishi Tanabe Pharma announced the termination of its exclusive sales rights agreements with AnGes for the HGF gene therapy product, Collategene (beperminogene perplasmid) intramuscular injection targeting peripheral arterial diseases in Japan and the USA. 23 August 2024
UK pharma major AstraZeneca has become the only current UK-lis¬ted company to reach a £200 billion ($256.4 billion) valuation, the Financial Times reported today, noting that it is a vindication of the company’s bet on developing a leading portfolio of cancer drugs. 14 August 2024
Japan’s Eisai and US biotech Biogen today revealed that the Ministry of Health and Prevention in the United Arab Emirates (UAE) has approved Leqembi (lecanemab) for the treatment of Alzheimer’s disease (AD). 14 August 2024
US pharma giant Pfizer has announced the publication of real-world results from a cohort of the longitudinal, observational Phase IV THAOS (Transthyretin Amyloidosis Outcomes Survey) study in the Journal of Cardiac Failure. 8 August 2024
Japanese drugmaker Shionogi says that its New Drug Application (NDA) for cefiderocol has been accepted for review by the Center for Drug Evaluation, National Medical Products Administration (NMPA). 5 August 2024
Germany’s Bayer has submitted to the US Food and Drug Administration for approval to market elinzanetant for moderate to severe vasomotor symptoms (VMS), commonly known as hot flashes, associated with menopause. 2 August 2024
Wednesday was a good day for US WorldMeds as the US Food and Drug Administration (FDA) moved a step closer to a potential approval of its New Drug Application (NDA) for eflornithine (DFMO). 5 October 2023
UK health technology assessor the National Institute for Health and Care Excellence (NICE) has backed the use of Jardiance (empagliflozin) for a new indication. 5 October 2023
Shares of US and UK-based gene therapy company Orchard Therapeutics almost doubled to $16.03 in pre-market activity today, on the news that it has received a takeover offer from mid-size Japanese drugmaker Kyowa Kirin. 5 October 2023
Rare diseases specialist Swedish Orphan Biovitrum, also known as Sobi, today announced that Lydia Abad-Franch has been appointed as senior vice president, head of research, development and medical affairs (RDMA), and chief medical office, a role which she has held on an interim basis since June. 5 October 2023
Shares of Melbourne, Australia-based Dimerix shot up 154% to A$0.16 on the news of a licensing deal with privately-held UK-based drugmaker Advanz Pharma. 5 October 2023
At an investor day in New York, Californian biotech Ionis Pharmaceuticals outlined key clinical and commercial updates related to its progress developing RNA-based medicines. 5 October 2023
On Wednesday, the US Food and Drug Administration published a new draft guidance to assist sponsors in developing treatments for stimulant use disorders. 5 October 2023
The government of Colombia plans to overcome patent barriers to HIV treatment and import low-cost generic versions of the HIV medicine dolutegravir without permission from the patent owner, ViiV Healthcare. 5 October 2023
French pharma major Sanofi (Euronext; SAN) has entered into a collaboration with the US subsidiary of global generics leader Israel-based Teva Pharmaceutical Industries (NYSE and TASE: TEVA). 4 October 2023
The market for biosimilar versions of AbbVie’s mega-blockbuster TNF blocker Humira (adalimumab) is hotting up, with a major price reduction from Boehringer Ingelheim. 4 October 2023
The UK is in a strong position to become “a global leader in mRNA medicine,” according to a new report by industry cheerleader the BioIndustry Association (BIA). 4 October 2023
Positive results from the T2NOW Phase III trial have demonstrated significant reduction in A1C, a marker of average blood sugar, for patients treated with Forxiga/Farxiga (dapagliflozin) compared to those receiving placebo. 4 October 2023
California-based Vistagen Therapeutics, a company aiming to transform the treatment landscape for anxiety, depression, and other central nervous system (CNS) disorders, has raised $100 million through an underwritten offering of its common stock. 4 October 2023
US pharma major Eli Lilly today revealed that Mike Mason, executive vice president and president of Lilly Diabetes and Obesity, will retire at the end of 2023 after 34 years with the company. 4 October 2023
US clinical-stage immuno-oncology company ALX Oncology Holdings saw its shares rocket 56% to $7.51 yesterday, as it announced positive clinical results for its lead asset after a previous disappointment. 4 October 2023
Positive results have been presented from the primary analysis of the ongoing RAINBOWFISH study assessing the efficacy and safety of Evrysdi (risdiplam) in babies with pre-symptomatic spinal muscular atrophy (SMA), aged from birth to six weeks. 4 October 2023
Danish diabetes care giant Novo Nordisk’s obesity medication Wegovy (semaglutide) will soon be accessible through the National Health Service (NHS) in England, albeit with limited supply. 4 October 2023